SCHEMBL10083307

SCHEMBL10083307

O=C(O)C1(c2cnc3ccccc3n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
HSD17B10 Q99714 1/20 0.50
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
PTK2 Q05397 1/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
AKR1C1 Q04828 1/20 0.41
MAPT P10636 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10083312 0.78 MGAM (0.49) ALDH1A1AKR1C3AKR1C2SMN1; SMN2NPSR1
SCHEMBL10083333 0.74 AKR1C3 (0.63) HSD17B10AKR1C3AKR1C2SMN1; SMN2KDM4E
SCHEMBL7422416 0.72 HSD11B1 (0.51) ALDH1A1KMT2AAKR1C1
SCHEMBL1759727 0.69 APP (0.40) AKR1C3AKR1C2AKR1C1
SCHEMBL350872 0.69 CHRM2 (0.45) ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2
SCHEMBL29623278 0.67 ALDH1A1 (1.00) ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2
SCHEMBL354679 0.67 ALDH1A1 (1.00) ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2
SCHEMBL30239786 0.67 SIRT6 (0.40) AKR1C3AKR1C2MEN1KMT2AAKR1C1
SCHEMBL8174635 0.67 ALDH1A1 (0.55) ALDH1A1HPGDALOX15HSD17B10SMN1; SMN2
SCHEMBL3104444 0.67 CHRM2 (0.43) ALDH1A1HPGDSMN1; SMN2NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9303027-B2 Kappa opioid receptor agonists DR. REDDY'S LABORATORIES LTD. (IN) 2016-04-05 US disclosed
US-9303027-B2 Kappa opioid receptor agonists DR. REDDY'S LABORATORIES LTD. (IN) 2016-04-05 US disclosed
US-20130303525-A1 KAPPA OPIOID RECEPTOR AGONISTS DR. REDDY'S LABORATORIES, INC. (US) 2013-11-14 US disclosed
US-20130303525-A1 KAPPA OPIOID RECEPTOR AGONISTS DR. REDDY'S LABORATORIES, INC. (US) 2013-11-14 US disclosed
WO-2012012410-A2 KAPPA OPIOID RECEPTOR AGONISTS DR. REDDY'S LABORATORIES LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303525-A1 KAPPA OPIOID RECEPTOR AGONISTS OPRK1, OPRL1, OPRD1 ALDH1A1 1649/4885HPGD 2679/4885ALOX15 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.